Comparison of four target volume definitions for pancreatic cancer: Guidelines for treatment of the lymphatics and the primary tumor

Strahlentherapie und Onkologie

Volumn 189, Issue 5, 2013, Pages 407-416

  Fokas, E ^a,b   Eccles, C ^a   Patel, N ^a   Chu, K Y ^a   Warren, S ^a   Gillies McKenna, W ^a   Brunner, T B ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Guidelines; Lymph nodes; Pancreatic cancer; Planning target volume; Primary tumor

Indexed keywords

ANATOMICAL VARIATION; AORTA; ARTICLE; CELIAC ARTERY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INFERIOR CAVA VEIN; LYMPH VESSEL METASTASIS; PANCREAS ADENOCARCINOMA; PARAAORTIC LYMPH NODE; PORTAL VEIN; PRIMARY TUMOR; RADIATION DOSE DISTRIBUTION; SUPERIOR MESENTERIC ARTERY; TREATMENT PLANNING; TUMOR VOLUME;

CARCINOMA, PANCREATIC DUCTAL; GERMANY; HUMANS; IMAGING, THREE-DIMENSIONAL; LYMPHATIC METASTASIS; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84877804757     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0332-3     Document Type: Article

References (25)

1. Stathis A, Moore MJ (2012) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163-172
2. Kessel KA, Habermehl D, Bohn C et al (2012) Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer. Strahlenther Onkol 188:1119-1124
3. Tinkl D, Grabenbauer GG, Golcher H et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185:557-566
4. Klautke G, Brunner TB (2008) Radiotherapy in pancreatic cancer. Strahlenther Onkol 184:557-564
5. Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813
6. Asiyanbola B, Gleisner A, Herman JM et al (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13:752-759
7. Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105-4112
8. Maluta S, Schaffer M, Pioli F et al (2011) Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187:619-625
9. Eppinga W, Lagerwaard F, Verbakel W et al (2010) Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 186:382-387
10. Murphy JD, Adusumilli S, Griffith KA et al (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801-808
11. Ben-Josef E, Schipper M, Francis IR et al (2011) Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 81:127-128
12. Brunner TB, Scott-Brown M (2010) The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 5:64
13. Ben-Josef E, Lawrence TS (2012) Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9:9-10
14. Brunner TB, Grabenbauer GG, Klein P et al (2003) Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55:144-153
15. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
16. Brunner TB, Merkel S, Grabenbauer GG et al (2005) Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 62:1021-1029
17. Brunner TB, Baum U, Grabenbauer GG et al (2006) Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning. Radiother Oncol 81:190-195
18. Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450-4456
19. Goodman KA, Regine WF, Dawson LA et al (2012) Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901-908
20. Spalding AC, Jee KW, Vineberg K et al (2007) Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 34:521-529
21. Zhao L, Chen M, Ten Haken R et al (2007) Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82:153-159
22. Sun W, Leong CN, Zhang Z, Lu JJ (2010) Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 5:28
23. Nagakawa T, Kobayashi H, Ueno K et al (1994) Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 73:1155-1162
24. Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25-33
25. Niedergethmann M, Rexin M, Hildenbrand R et al (2002) Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 26:1578-1587